底物包膜与耐药性：RO1与野生型人类免疫缺陷病毒1型蛋白酶复合物的晶体结构
Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease.
作者信息
Prabu-Jeyabalan Moses, King Nancy M, Nalivaika Ellen A, Heilek-Snyder Gabrielle, Cammack Nick, Schiffer Celia A
机构信息
Department of Biochemistry & Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation St., Worcester, MA 01605, USA.
出版信息
Antimicrob Agents Chemother. 2006 Apr;50(4):1518-21. doi: 10.1128/AAC.50.4.1518-1521.2006.
Abstract
In our previous crystallographic studies of human immunodeficiency virus type 1 (HIV-1) protease-substrate complexes, we described a conserved "envelope" that appears to be important for substrate recognition and the selection of drug-resistant mutations. In this study, the complex of HIV-1 protease with the inhibitor RO1 was determined and comparison with the substrate envelope provides a rationale for mutational patterns.
摘要
在我们之前对1型人类免疫缺陷病毒（HIV-1）蛋白酶-底物复合物的晶体学研究中，我们描述了一个保守的“包膜”，它似乎对底物识别和耐药性突变的选择很重要。在本研究中，确定了HIV-1蛋白酶与抑制剂RO1的复合物，并与底物包膜进行比较，为突变模式提供了理论依据。
相似文献
1
Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease.底物包膜与耐药性：RO1与野生型人类免疫缺陷病毒1型蛋白酶复合物的晶体结构
Antimicrob Agents Chemother. 2006 Apr;50(4):1518-21. doi: 10.1128/AAC.50.4.1518-1521.2006.
2
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.评估底物-囊泡假说：设计用于抵抗耐药性的新型 HIV-1 蛋白酶抑制剂的结构分析。
J Virol. 2010 May;84(10):5368-78. doi: 10.1128/JVI.02531-09. Epub 2010 Mar 17.
3
A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.一种针对HIV-1蛋白酶耐药性突变的结构和热力学逃逸机制。
Proteins. 2004 May 15;55(3):594-602. doi: 10.1002/prot.20069.
4
Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.对HIV-1蛋白酶抑制剂的底物包膜假说的评估。
Proteins. 2007 Aug 1;68(2):561-7. doi: 10.1002/prot.21431.
5
Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.结晶学研究多药耐药 HIV-1 蛋白酶洛匹那韦复合物：药物识别和耐药机制。
Biochem Biophys Res Commun. 2013 Jul 26;437(2):199-204. doi: 10.1016/j.bbrc.2013.06.027. Epub 2013 Jun 18.
6
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.基于底物包膜假说设计抗突变的HIV蛋白酶抑制剂
Chem Biol Drug Des. 2007 May;69(5):298-313. doi: 10.1111/j.1747-0285.2007.00514.x.
7
Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex.耐药机制的研究进展：多药耐药 HIV-1 蛋白酶利托那韦复合物的 X 射线晶体结构分析。
Biochem Biophys Res Commun. 2013 Feb 8;431(2):232-8. doi: 10.1016/j.bbrc.2012.12.127. Epub 2013 Jan 8.
8
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease.赖氨酸磺酰胺抑制剂的晶体结构揭示了1型人类免疫缺陷病毒蛋白酶中保守的活性中心水分子的置换。
J Virol. 2007 Sep;81(17):9512-8. doi: 10.1128/JVI.00799-07. Epub 2007 Jun 27.
9
Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.含有羟甲基羰基电子等排体作为理想过渡态模拟物的基于小肽的HIV蛋白酶抑制剂。
Biopolymers. 1999;51(1):59-68. doi: 10.1002/(SICI)1097-0282(1999)51:1<59::AID-BIP7>3.0.CO;2-3.
10
Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.1型人类免疫缺陷病毒蛋白酶对奈非那韦的耐药机制。
J Phys Chem B. 2005 Jan 13;109(1):565-74. doi: 10.1021/jp046860+.
引用本文的文献
1
Factors Influencing the Binding of HIV-1 Protease Inhibitors: Insights from Machine Learning Models.影响HIV-1蛋白酶抑制剂结合的因素：来自机器学习模型的见解
ChemMedChem. 2025 Aug 2;20(15):e202500277. doi: 10.1002/cmdc.202500277. Epub 2025 Jun 21.
2
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.HIV 整合酶的多方面功能及其抑制的治疗策略。
J Biol Chem. 2019 Oct 11;294(41):15137-15157. doi: 10.1074/jbc.REV119.006901. Epub 2019 Aug 29.
3
HIV protease inhibitors: a review of molecular selectivity and toxicity.HIV蛋白酶抑制剂：分子选择性与毒性综述
HIV AIDS (Auckl). 2015 Apr 8;7:95-104. doi: 10.2147/HIV.S79956. eCollection 2015.
4
A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.虚拟筛选发现结核分枝杆菌InhA的新型片段大小抑制剂。
J Chem Inf Model. 2015 Mar 23;55(3):645-59. doi: 10.1021/ci500672v. Epub 2015 Feb 17.
5
Drug Resistance Mutations Alter Dynamics of Inhibitor-Bound HIV-1 Protease.耐药性突变改变与抑制剂结合的HIV-1蛋白酶的动力学。
J Chem Theory Comput. 2014 Aug 12;10(8):3438-3448. doi: 10.1021/ct4010454. Epub 2014 Jun 12.
6
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.一种HIV-1蛋白酶的变构调节剂对野生型和耐药蛋白酶具有同等效力的抑制作用。
J Med Chem. 2014 Aug 14;57(15):6468-78. doi: 10.1021/jm5008352. Epub 2014 Aug 1.
7
Kinetic characterization of the critical step in HIV-1 protease maturation.HIV-1 蛋白酶成熟过程中关键步骤的动力学特征。
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20449-54. doi: 10.1073/pnas.1210983109. Epub 2012 Nov 26.
8
Backbone ¹H, ¹³C, and ¹⁵N chemical shift assignment for HIV-1 protease subtypes and multi-drug resistant variant MDR 769.HIV-1蛋白酶亚型和多药耐药变体MDR 769的主链¹H、¹³C和¹⁵N化学位移归属
Biomol NMR Assign. 2013 Oct;7(2):199-202. doi: 10.1007/s12104-012-9409-7. Epub 2012 Jul 1.
9
Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease.HIV-1 蛋白酶耐药变异体中的极端熵-焓补偿。
ACS Chem Biol. 2012 Sep 21;7(9):1536-46. doi: 10.1021/cb300191k. Epub 2012 Jul 2.
10
Role of Gag in HIV Resistance to Protease Inhibitors.Gag 在 HIV 对蛋白酶抑制剂的耐药性中的作用。
Viruses. 2010 Jul;2(7):1411-1426. doi: 10.3390/v2071411. Epub 2010 Jul 5.
本文引用的文献
1
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.1型人类免疫缺陷病毒核衣壳-p1裂解位点与病毒蛋白酶中V82A耐药突变协同进化的结构基础
J Virol. 2004 Nov;78(22):12446-54. doi: 10.1128/JVI.78.22.12446-12454.2004.
2
Combating susceptibility to drug resistance: lessons from HIV-1 protease.对抗耐药性易感性：来自HIV-1蛋白酶的经验教训。
Chem Biol. 2004 Oct;11(10):1333-8. doi: 10.1016/j.chembiol.2004.08.010.
3
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.下一代1型人类免疫缺陷病毒蛋白酶抑制剂TMC114结合的结构和热力学基础
J Virol. 2004 Nov;78(21):12012-21. doi: 10.1128/JVI.78.21.12012-12021.2004.
4
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.蛋白酶抑制剂耐药谱对初治患者抗HIV治疗选择的影响。
Antivir Ther. 2004 Jun;9(3):301-14.
5
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.通过表型相关性改进洛匹那韦基因型算法：新的突变模式和安普那韦交叉耐药性。
AIDS. 2003 May 2;17(7):955-61. doi: 10.1097/00002030-200305020-00003.
6
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy.一种耐药性人类免疫缺陷病毒1型蛋白酶变体的生存能力：为更好的抗病毒治疗提供结构见解。
J Virol. 2003 Jan;77(2):1306-15. doi: 10.1128/jvi.77.2.1306-1315.2003.
7
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes.底物形状决定HIV-1蛋白酶识别的特异性：六种底物复合物晶体结构分析
Structure. 2002 Mar;10(3):369-81. doi: 10.1016/s0969-2126(02)00720-7.
8
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database.人类免疫缺陷病毒逆转录酶和蛋白酶序列数据库
Nucleic Acids Res. 1999 Jan 1;27(1):348-52. doi: 10.1093/nar/27.1.348.
9
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.对新型蛋白酶抑制剂ABT-378具有更高抗性的1型人类免疫缺陷病毒变体的体外筛选与特性分析
J Virol. 1998 Sep;72(9):7532-41. doi: 10.1128/JVI.72.9.7532-7541.1998.
10
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.佳息患（奈非那韦甲磺酸盐，AG1343）：一种强效的、口服生物利用度良好的HIV-1蛋白酶抑制剂。
J Med Chem. 1997 Nov 21;40(24):3979-85. doi: 10.1021/jm9704098.
Zotero 插件